US EditionEli Lilly Co. Q2 FY2025 Earnings Transcript - Eli Lilly (NYSE:LLY)
NEW YORK, AUG 7 – Orforglipron's weight-loss results lag behind competitors, triggering a 12% drop in Eli Lilly shares despite strong earnings and raised revenue forecasts for the full year.
- On Thursday, Eli Lilly shares declined as much as 12% in New York premarket trading after trial data for its new weight-loss drug showed underperformance despite strong earnings.
- On Thursday, Eli Lilly's experimental weight-loss pill delivered a 12.4% body weight reduction over 72 weeks but fell short of the 15% benchmark set by Wegovy over 68 weeks.
- Lilly lifted sales and EPS guidance, with full-year estimates now at $60B–$62B and $21.75–$23.00, surpassing Wall Street expectations.
- Lilly's share decline sparked bids in Novo Nordisk shares, and if losses hold through the cash session, it could mark the largest single-day drop since Oct. 9, 2008.
- The U.S. Food and Drug Administration is reviewing a high-dose oral Wegovy for potential approval later this year, and Lilly plans to file for approval before the end of 2025, as analysts project the market will reach $150 billion by the early 2030s.
Insights by Ground AI
Does this summary seem wrong?
24 Articles
24 Articles
Why Eli Lilly Stock Is Plunging Today @themotleyfool #stocks $LLY
Key PointsLilly's orforglipron achieved less weight loss than some Wall Street analysts expected.The relatively high patient discontinuation rate in the phase 3 study of the drug also raised eyebrows.Orforglipron could still become a big winner for Lilly, though.10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for the second quarter o…
·Alexandria, United States
Read Full Article
Eli Lilly shares tumble over 10% after disappointing weight-loss pill data
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting than anticipated, side effects associated with so-called GLP-1 drugs
·New Delhi, India
Read Full Article
Coverage Details
Total News Sources24
Leaning Left4Leaning Right2Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 31%
C 54%
15%
Factuality
To view factuality data please Upgrade to Premium
